INVA · Innoviva, Inc.
$21.44
+2.39% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
3.4
Forward P/E
9.6
Dividend yield
—
Beta
0.34
Avg volume
1M
Employees
0K
2D change
—
5D change
0.47%
10D change
-1.89%
30D change
-9.63%
60D change
-0.56%
MTD change
-2.74%
YTD change
6.55%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INVA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-22
Latest call per bank · past 12 months
Goldman Sachs
Sell$17.00
-20.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-22 | BTIG | Maintains | Buy | $42.00 |
| 2026-06-01 | HC Wainwright & Co. | Reiterates | Buy | $46.00 |
| 2026-05-26 | BTIG | Reiterates | Buy | $42.00 |
| 2026-05-07 | BTIG | Maintains | Buy | $35.00 → $42.00 |
| 2026-02-26 | BTIG | Reiterates | Buy | $35.00 |
| 2026-02-17 | BTIG | Initiates | Buy | $0.00 → $35.00 |
| 2025-12-16 | HC Wainwright & Co. | Maintains | Buy | $45.00 → $46.00 |
| 2025-11-06 | Cantor Fitzgerald | Maintains | Overweight | $29.00 → $31.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.9% below the 50-day MA ($22.24).
- Price vs 200-day MA: Trading 1.7% above the 200-day MA ($21.44).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.67) and high ($24.24).
INVA Price Chart
Loading chart for INVA…
Fundamentals
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.